T. Rowe Price Investment Management Inc. Purchases 435,445 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

T. Rowe Price Investment Management Inc. increased its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 40.5% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,509,332 shares of the medical equipment provider's stock after purchasing an additional 435,445 shares during the period. T. Rowe Price Investment Management Inc. owned approximately 2.17% of Lantheus worth $135,025,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in LNTH. Wilmington Savings Fund Society FSB purchased a new position in shares of Lantheus during the 3rd quarter worth approximately $25,000. Kestra Investment Management LLC acquired a new position in Lantheus during the fourth quarter worth $27,000. Summit Securities Group LLC purchased a new position in Lantheus in the fourth quarter worth $37,000. UMB Bank n.a. lifted its holdings in Lantheus by 31.5% in the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock valued at $50,000 after acquiring an additional 134 shares during the period. Finally, World Investment Advisors LLC purchased a new stake in shares of Lantheus during the 3rd quarter worth $60,000. Institutional investors and hedge funds own 99.06% of the company's stock.

Insider Buying and Selling at Lantheus

In related news, Director Mary Anne Heino sold 53,107 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the sale, the director now directly owns 440,399 shares in the company, valued at approximately $41,551,645.65. This trade represents a 10.76 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the firm's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the sale, the chief financial officer now directly owns 113,860 shares of the company's stock, valued at approximately $11,445,207.20. This represents a 8.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 63,109 shares of company stock worth $6,016,046 over the last 90 days. Insiders own 1.50% of the company's stock.

Analysts Set New Price Targets

LNTH has been the subject of several recent analyst reports. B. Riley reduced their price objective on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research note on Friday, March 21st. Truist Financial lifted their price target on shares of Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a research report on Thursday, February 27th. Finally, JMP Securities restated a "market outperform" rating and issued a $112.00 price target on shares of Lantheus in a report on Tuesday, January 14th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $129.43.

Lantheus Price Performance

Lantheus stock traded up $0.45 during midday trading on Wednesday, hitting $104.41. 192,486 shares of the stock were exchanged, compared to its average volume of 950,506. Lantheus Holdings, Inc. has a 1 year low of $65.89 and a 1 year high of $126.89. The company has a 50 day moving average price of $98.26 and a two-hundred day moving average price of $95.14. The firm has a market cap of $7.15 billion, a P/E ratio of 17.37 and a beta of 0.20.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The firm had revenue of $391.11 million during the quarter, compared to analyst estimates of $376.61 million. As a group, analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.